Aim: Proteasome inhibitors have been found to suppress glioma cell proliferation and induce apoptosis, but the mechanisms are not fully elucidated. In this study we investigated the mechanisms underlying the apoptosis induced by the proteasome inhibitor MG-132 in glioma cells. Methods: C6 glioma cells were used. MTT assay was used to analyze cell proliferation. Proteasome activity was assayed using Succinyl-LLVY-AMC, and intracellular ROS level was evaluated with the redox-sensitive dye DCFH-DA. Apoptosis was detected using fluorescence and transmission electron microscopy as well as flow cytometry. The expression of apoptosis-related proteins was investigated using Western blot analysis. Results: MG-132 inhibited C6 glioma cell proliferation in a time-and dose-dependent manner (the IC 50 value at 24 h was 18.5 μmol/L). MG-132 (18.5 μmol/L) suppressed the proteasome activity by about 70% at 3 h. It induced apoptosis via down-regulation of antiapoptotic proteins Bcl-2 and XIAP, up-regulation of pro-apoptotic protein Bax and caspase-3, and production of cleaved C-terminal 85 kDa PARP). It also caused a more than 5-fold increase of reactive oxygen species. Tiron (1 mmol/L) effectively blocked oxidative stress induced by MG-132 (18.5 μmol/L), attenuated proliferation inhibition and apoptosis in C6 glioma cells, and reversed the expression pattern of apoptosis-related proteins. Conclusion: MG-132 induced apoptosis of C6 glioma cells via the oxidative stress.
Introduction
The proteasome is an evolutionarily conserved protease complex with multiple catalytic activities and is mainly responsible for selective degradation of abnormal intracellular proteins and many cellular regulatory proteins [1] . It is also involved in cellular differentiation, antigen presentation and cell cycle modulation [2] . Therefore, inhibition of proteasome activity has emerged as a new chemotherapy strategy for malignant tumors. Although studies have shown that inhibition of proteasome activity could inhibit cellular proliferation in several tumor cell lines including melanoma, prostate cancer and glioma cells [3] [4] [5] [6] , its underlying mechanism is not fully understood. The proteasome inhibitor bortezomib has been authorized by the US Food and Drug Administration to enter clinical trials, but it is used mainly in the leukemia field. Thus, more studies are needed to investigate the effects of proteasome inhibition on solid cancers. MG-132 is an aldehyde peptide compound that has shown potent inhibitory effects on proteasome chymotrypsin-like activity and is chemically distinct from bortezomib (a boronic acid dipeptide) [7] . Although our previous studies in vitro showed that it could induce apoptosis in human glioma cells [8] , its upstream events are largely unknown.
Oxidative stress is a complex and dynamic situation characterized by overproduction of reactive oxygen species (ROS) that cannot be cleared from cells [9] . Oxidative stress can damage macromolecules such as lipids, nucleic acids and proteins and trigger cell death through the effects of ROS on signal transduction pathways [10] . Therefore, oxidative stress could cause cell death via apoptotic pathways. Several studies have shown that oxidative stress is closely associated with Proteasome inhibitor MG-132 induces C6 glioma cell apoptosis via oxidative stress the proteasome, as the proteasome is involved in regulating anti-oxidants, including catalase, heme oxygenase-1 (HO-1), copper/zinc-superoxide dismutase and γ-GCS [11] [12] [13] [14] . However, the relationship between proteasome dysfunction and oxidative stress is still a matter of dispute. In the central nervous system, proteasome dysfunction serves as an important switch for the induction of oxidative stress [15] . On the other hand, proteasome inhibition has protective effects on vascular cells undergoing oxidative stress [14] . Even for tumor cells, proteasome inhibition also has varied effects on the production of ROS in different thyroid cancer cell lines [16] . Therefore, in this study, we examined the effects of proteasome inhibition on rat C6 glioma cells and investigated the relationship between apoptosis and oxidative stress generated by inhibition of proteasome activity. Thus, tiron (4,5-dihydroxy-1,3-benzene disulfonic acid), a well-known and widely used antioxidant [17] , was used in this study to attenuate the oxidative stress that proteasome inhibition might induce.
Materials and methods
Reagents MG-132, obtained from Calbiochem (San Diego, CA, USA), was dissolved in PBS to a storage concentration of 50 μmol/L. DMEM medium was from Gibco (Rockville, MD, USA). Fetal bovine serum (FBS) was from Life Technologies (Grand Island, NY, USA). Antibodies against caspase-3, Bax, and Bcl-2 were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-XIAP (X chromosome-linked inhibitor of apoptosis) was from R&D systems (Minneapolis, MN, USA). Anti-poly (ADPribose) polymerase (PARP) and PARP/85 were from BD Biosciences (San Jose, CA, USA). Protein concentration assay kits were from Bio-Rad (Hercules, CA, USA). ECL Western blotting detection reagents were from Amersham (Piscataway, NJ, USA). PVDF membranes were from Millipore Company (Billerica, MA, USA). Other reagents were from Sigma (St Louis, MO, USA).
Cell line and culture
Rat C6 glioma cells were obtained from Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). Cells were cultured in DMEM supplemented with 10% fetal bovine serum, 2 mmol/L glutamine (Gibco, Grand Island, NY, USA), penicillin (100 U/mL) and streptomycin (100 μg/mL) and maintained at 37 ºC and 5% CO 2 in a humid environment. Cells in the mid-log phase were used for experiments.
Cell viability assay C6 glioma cells were seeded onto 96-well microplates (3×10 4 cells/well) and cultured for 24 h. The cells were treated with PBS or MG-132 final concentrations of 10, 20, 30, and 40 µmol/L, respectively. Cell viability was assessed using an MTT assay at 3, 6, 12, and 24 h after MG-132 treatment. The absorbance value (A) at 570 nm was read using an automatic multi-well spectrophotometer (Bio-Rad, Richmond, CA, USA). Transmission electron microscopy C6 glioma cells were cultured and treated as described above and harvested using 0.25% trypsin and washed with PBS. Then the cells were collected by centrifugation at 800×g for 10 min and treated as described by Watkins and Cullen [18] . Briefly, the cells were fixed in ice-cold 2.5% glutaraldehyde in PBS (pH 7.3), rinsed with PBS and post-fixed in 1% osmium tetroxide with 0.1% potassium ferricyanide, dehydrated through a graded series of ethanol (30%-90%) and embedded in Epon (Energy Beam Sciences, Agawam, MA, USA). Semithin (300 nm) sections were cut using a Reichart Ultracut, stained with 0.5% toluidine blue and examined under a light microscope. Ultrathin sections (65 nm) were stained with 1% uranyl acetate and 0.1% lead citrate and examined on a JEM2000EX transmission electron microscope (JEOL, Pleasanton, CA, USA).
Proteasome activity assay
After growing on six-well plates (3×10 5 cells/well) for 24 h, C6 glioma cells were treated with either PBS (control) or 18.5 µmol/L MG-132 for 3, 6, 12, or 24 h at 37 ºC. Cells were thoroughly scraped from the culture dishes with a cell scraper and washed with cold PBS. After centrifugation for 10 min at 800×g, the cell pellets were suspended in ice-cold buffer (50 mmol/L Tris-HCl, pH 7.5, 20 µmol/L ATP, 5 mmol/L MgCl 2 , 1 mmol/L dithiothreitol, and 20% glycerol) and homogenized with a Pyrex glass microhomogenizer (20 strokes). The homogenate was centrifuged at 15 000×g for 10 min at 4 °C to obtain supernatant. Protein concentration was determined using protein assay kits (Bio-Rad Laboratories). A total of 10 µL (1 µg/µL) of each freshly made supernatant was incubated in a 96-well plate at 37 °C for 30 min with 10 µL of 300 µmol/L of Succinyl-LLVY-AMC (Calbiochem, San Diego, CA, USA) and 85 µL of assay buffer (20 mmol/L Tris-HCl, pH 7.5, and 20% glycerol). Release of fluorescent AMC was measured with a spectrofluorometer (Perkin-Elmer Life and Analytical Sciences, Inc, Wellesley, MA, USA) at 440 nm with an excitation wavelength of 380 nm.
Measurement of intracellular ROS levels
The average level of intracellular ROS in C6 glioma cells was evaluated in cells loaded with the redox-sensitive dye DCFH-DA (Molecular Probes, OR, USA). Cells treated with 18.5 µmol/L MG-132 alone were examined at 3, 6, 12, or 24 h; cells Western blotting C6 glioma cells were cultured, harvested and washed as described above. After centrifugation for 10 min at 1000×g, the cell pellets were suspended in ice-cold buffer (15 mmol/L Tris, pH 7.6, 250 mmol/L sucrose, 1 mmol/L MgCl 2 , 2.5 mmol/L EDTA, 1 mmol/L EGTA (ethylene glycol-bis (b-amino ethylether) tetraacetic acid), 1 mmol/L dithiothreitol, 1.25 mg/mL pepstatin A, 10 mg/mL leupeptin, 2.5 mg/mL aprotinin, 1.0 mmol/L phenylmethylsulfonyl fluoride (PMSF), 0.1 mmol/L Na 3 VO 4 , 50 mmol/L NaF, and 2.0 mmol/L Na 4 P 2 O 7 ) and homogenized with a Pyrex glass microhomogenizer (20 strokes). Homogenates were centrifuged at 10 000×g at 4 o C for 10 min to obtain supernatant. The protein content of the supernatant was determined using Bio-Rad protein assay kits.
Equal amounts of protein were electrophoresed on 10% sodium dodecyl sulfate-polyacrylamide gels and then transferred to PVDF membranes. The membranes were blocked with 3% bovine serum albumin in TBS for 30 min and then incubated overnight at 4 °C with the following primary antibodies: caspase-3, Bax, Bcl-2, XIAP, PARP, PARP/85, and β-actin. After being incubated with horseradish peroxidaseconjugated anti-rabbit IgG or anti-mouse IgG, the blots were washed, and immunoreactive proteins were visualized on Kodak X-omat LS film (Eastman Kodak Company, New Haven, CT, USA) with an enhanced chemiluminescence kit (Amersham Biosciences, Piscataway, NJ, USA). Densitometry was performed with Kodak ID image analysis software (Eastman Kodak Company).
Statistical analysis
All data represent at least 4 independent experiments and are expressed as the mean±SD. Statistical comparisons were made using Student's t-test. P values of less than 0.05 were considered significant.
Results
MG-132 inhibited C6 glioma cell proliferation and inhibited proteasome chymotrypsin-like activity MG-132 significantly reduced the viability of C6 glioma cells beginning at 6 h in both time-and concentration-dependent manners ( Figure 1A) . At 24 h, the inhibitory effect reached a maximum, with inhibition rates of 23%, 45%, 73%, and 90% at concentrations of 10, 20, 30, and 40 μmol/L, respectively. The IC 50 of MG-132 at 24 h was 18.5 μmol/L. Then, we assayed the inhibitory effect of 18.5 μmol/L MG-132 on proteasomal chymotrypsin-like activity using Succinyl-LLVY-AMC as a specific substrate [18] . MG-132 gradually inhibited enzymatic activity from 3 to 24 h (P<0.01, Figure 1B ). This result suggested that 18.5 μmol/L MG-132 could effectively suppress proteasome activity and that proteasome inhibition occurred earlier (3 h) than that of viability reduction (6 h). Figure  2C ), indicating that the effects of MG-132 in C6 glioma cells might be due partly to oxidative stress.
Tiron suppressed MG-132-induced apoptosis and cell cycle arrest
Chromatin accumulation under the nuclear membrane, nuclear condensation and DNA fragmentation were revealed by both fluorescence microscopy and transmission electron microscopy after C6 glioma cells were treated with 18.5 μmol/L MG-132 for 24 h (Figure 3 ). These morphological features were consistent with the characteristics of apoptosis reported previously [18] , indicating that apoptosis was induced by MG-132 in C6 glioma cells. Subsequent examination by flow cytometry showed that tiron suppressed MG-132-induced apoptosis in C6 glioma cells. The apoptosis rate decreased from 30.46% to 20.79%, and the percentage of cells arrested in G 2 /M phase was reduced from 17.31% to 12.77% (Figure 4) . These results suggest that the apoptosis induced by MG-132 was closely associated with oxidative stress.
Tiron attenuated the expression of apoptosis-related proteins Previous studies have shown that the expression of apoptotic machinery proteins such as Bcl-2, XIAP (X chromosome-linked inhibitor of apoptosis), Bax, caspase-3, and PARP is altered by oxidative stress [19] . In the present study, Western blot analysis revealed that the expressional level of pro-apoptotic proteins Bax and caspase-3 increased significantly, whereas the expressional level of anti-apoptotic proteins Bcl-2 and XIAP decreased markedly after C6 glioma cells were incubated with 18.5 μmol/L MG-132 for 24 h ( Figure 5 ). However, tiron attenuated the MG-132-induced expression patterns of the abovementioned pro-apoptotic and anti-apoptotic proteins ( Figure  5 ). Meanwhile, tiron significantly reduced the quantity of cleaved PARP as well ( Figure 5 ). These results indicated that tiron rescues MG-132-induced apoptosis in C6 glioma cells by influencing the expression of apoptosis-related proteins.
Discussion
In this study, we found that MG-132, a competitive inhibitor of proteasome chymotrypsin-like activity, induces apoptosis of C6 glioma cells via oxidative stress. We found that proteasome activity is increased in malignant cells derived from different types of cancer as compared with normal cells [20] , indi- Although it has been reported that nontoxic proteasome inhibition protected cells from oxidative stress [21] , our results showed that proteasome inhibitor MG-132 at toxic concentrations could generate oxidative stress and induce apoptosis in glioma cells. Oxidative stress has been demonstrated to be closely associated with cellular death in various tumor cells [9, 16, 22] . Studies investigating the relationship between oxidative stress and apoptosis have indicated that oxidative stress may be a precursor to apoptosis in C6 glioma cells [23, 24] . In the present study, we found that selective inhibition of proteasome activity by MG-132 produced a cause-effect relationship between oxidative stress and apoptosis in rat C6 glioma cells.
Although we did not further investigate the mechanism underlying the oxidative stress produced via the inhibition of proteasome activity, previous reports showed that abnormal or unfolded intracellular proteins would aggregate if they could not be degraded via the proteasome pathway, leading to the generation of reactive oxygen species, the most prominent marker of oxidative stress [25] . In addition, the present study showed that blocking oxidative stress with the anti-oxidant tiron attenuated the decreased expression of Bcl-2 and XIAP, both of which are not only anti-apoptotic factors but also function as regulators of antioxidants [26, 27] . Bcl-2 increases cellular resistance to H 2 O 2 by increasing glutathione levels and Cu/Zn-superoxide dismutase (SOD1) activity [28] . XIAP induces up-regulation of at [29] . Therefore, decreased expression of Bcl-2 and XIAP would exacerbate the severity of oxidative stress caused by MG-132, forming a malignant feedback loop.
In addition to our findings on the alterations of anti-apoptotic and pro-apoptotic proteins in the present study, previous studies have revealed some typical features of apoptosis when glioma cells were treated with different proteasome inhibitors. It has been reported that MG-132 could trigger cytochrome c release and disruption of mitochondrial membrane potential, which were concurrent with DNA breaks and loss of membrane integrity. Further studies showed that proteasome inhibitor-induced apoptosis was dependent on caspases because multiple caspases such as caspase 2, 3, 7, 8, and 9 were activated and apoptosis was inhibited when glioma cells were exposed to the broad-spectrum caspase inhibitor zVADfmk (benzoyl-VAD-fluoromethyl ketone). Additionally, proteasome inhibitors could reduce the transcriptional activity and expression level of anti-apoptotic nuclear NF-kappaB [30] . These findings indicated that inhibition of proteasome activity is an effective strategy for inducing apoptosis in glioma cells.
Proteasome inhibitors could also activate intracellular signaling pathways. However, activation of the PI3K/AKT pathways impaired the response of tumor cells to proteasome inhibitor treatment, and inhibition of the PI3K/AKT pathways increased the antitumor effects of proteasome inhibitors [31] . By contrast, activation of the JNK/c-Jun pathway was closely associated with growth inhibition in human glioblastoma cells [5] . In addition to biochemical changes, morphological alteration is an important criterion for evaluating apoptosis. As described previously [18] , apoptotic changes in morphology such as chromatin accumulation, nuclear condensation and DNA fragmentation were observed in the present study. Moreover, dilated rough endoplasmic reticulum (ER), dense mitochondrial deposits and cytoplasmic vacuolization could be found when proteasome activity was inhibited [30] . Interestingly, these non-apoptotic alterations could still exist even if zVAD-fmk was used to block apoptosis, indicating that proteasome inhibition might lead to cellular death via another mechanism.
In summary, we showed that inhibition of proteasome activity by MG-132 is an effective way to suppress the proliferation of C6 glioma cells via the induction of apoptosis. Tiron not only blocked the oxidative stress caused by MG-132 but also suppressed MG-132-induced apoptosis by decreasing the expression of Bax and caspase-3, rescuing the expression of Bcl-2 and XIAP and attenuating PARP cleavage. These results suggest that there is a cause and effect relationship between oxidative stress and apoptosis induced by . Although the present study demonstrated that the inhibition of proteasome activity induced apoptosis in C6 glioma cells via oxidative stress, further research is needed to evaluate this phenomenon on solid gliomas in vivo.
